Home World News How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early... World News How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? By Ogkologos - November 3, 2026 9 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Διαφημιστείτε January 18, 2019 FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... March 6, 2025 Into the archives: the story of HPV and cervical cancer November 21, 2022 Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for... May 19, 2026 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma... Some People with Rectal Cancer Can Skip Radiation Before Surgery Grandparents of children with cancer: “I would never want to go... Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated...
